MedTrace Logo

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

NCT02482753 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2022-01-12

No results posted yet for this study

Summary

This study was to evaluate the efficacy and safety of Chidamide in combination with exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer.

Conditions

Interventions

DRUG

Chidamide

30 mg, administered orally twice per week (BIW)

DRUG

exemestane

25 mg, PO daily

DRUG

placebo

Administered orally twice per week (BIW)

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • Zefei Jiang · 307 Hospital of PLA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-03-31
Completion
2021-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02482753 on ClinicalTrials.gov